3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
1
Dementia
1
Alzheimer Disease
1
Interventions
Rituximab
91
Cyclophosphamide
31
Lenalidomide
28
Bendamustine Hydrochloride
25
Prednisone
21
Vincristine
20
obinutuzumab
17
Doxorubicin
17
fludarabine
14
ibrutinib
13
tazemetostat
9
idelalisib
9
Prednisolone
9
Deoxycholic Acid
9
parsaclisib
8
zanubrutinib
7
venetoclax
7
tofacitinib
7
tisagenlecleucel
5
pembrolizumab
5
ofatumumab
5
ibritumomab tiuxetan
5
duvelisib
5
Gemcitabine
5
Bortezomib
5
durvalumab
4
aflibercept
4
R-CHOP protocol
4
Methylprednisolone
4
Methotrexate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Follicular
×
UE2343
×
Clear all
NCT06125951
2026-04-23
XanaMIA
Actinogen Medical
Phase 2/3
Active not recruiting
247 enrolled